The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
Authors:
Open Access
- 18 November 2015
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 29 (6) , 365-372
Abstract
Biosimilars are required to be similar or highly similar in structure to their biologic reference product but are neither expected nor required to contain identical active substances. For example, glycosylated biosimilars approved to date demonstrate quantitative and qualitative structural differences from their reference product and exemplify the latitude of variations permitted for biosimilars. Although differences between a candidate biosimilar and its reference product will be evaluated for differential clinical effects during biosimilarity assessment, it is unlikely that potential differences between any two indirectly related biosimilars will be formally evaluated. Furthermore, biosimilar pathways permit variations in pharmaceutical attributes, clinical development approaches, and regulatory outcomes, resulting in further diversity of attributes among approved biosimilars. Because biosimilars may vary across the ranges of structural and functional acceptance criteria, they should not be treated like multisource, generic drugs.Keywords
Funding Information
- Amgen Inc.
This publication has 15 references indexed in Scilit:
- Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilarsExpert Opinion on Drug Safety, 2015
- Similar Names for Similar BiologicsBioDrugs, 2014
- Characterization of N‐glycan heterogeneities of erythropoietin products by liquid chromatography/mass spectrometry and multivariate analysisRapid Communications in Mass Spectrometry, 2014
- Drift, Evolution, and Divergence in Biologics and Biosimilars ManufacturingBioDrugs, 2014
- Biologic product identification and US pharmacovigilance in the biosimilars eraNature Biotechnology, 2014
- Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MSJournal of Pharmaceutical and Biomedical Analysis, 2013
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous applicationDrug Testing and Analysis, 2011
- Developing the Nation's Biosimilars ProgramNew England Journal of Medicine, 2011
- The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringesKidney International, 2005